In this regard, drugs targeting acetylation such as HDAC6 (histone deacetylase 6) inhibitors have been investigated for the treatment of depression, cancer, stroke, environmental stress and Huntington's disease (Dompierre et al., 2007; Lazo-Gómez et al., 2013; Simoes-Pires et al., 2013; Jochems et al., 2014; Brindisi et al., 2016, 2018; Ceccacci and Minucci, 2016; Wang et al., 2016; Rao et al., 2017). Here, HDAC6 is linked to cancer.